The most domestically selling meningococcemia vaccine, ‘Menveo’ to make a fresh start in GSK
The most famous traditional vaccine company, GSK(GlaxoSmithKline), acquired product approval for ‘Menveo,’ the most domestically selling meningococcemia vaccine, from the 31st of August.
This is execution of the agreement for GSK to take over the Novartis’s vaccine department on April 2014; ther...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
